59 results on '"Hendlisz A"'
Search Results
2. Systematic review and meta-analysis of local resection or transanal endoscopic microsurgery versus radical resection in stage i rectal cancer: A real standard?
3. Results of a single-arm pilot study of 32P microparticles in unresectable locally advanced pancreatic adenocarcinoma with gemcitabine/nab-paclitaxel or FOLFIRINOX chemotherapy.
4. Tumor biology reflected by histological growth pattern is more important than surgical margin for the prognosis of patients undergoing resection of colorectal liver metastases.
5. Non-operative management after immune checkpoint inhibitors for early-stage, dMMR/MSI-H gastrointestinal cancers.
6. Targeted agents in older patients with gastrointestinal cancers – An overview.
7. The absence of benefit of perioperative chemotherapy in initially resectable peritoneal metastases of colorectal cancer origin treated with complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: A retrospective analysis.
8. Neoadjuvant chemotherapy for early-stage colon cancer.
9. MOMENTUM: A Phase I Trial Investigating 2 Schedules of Capecitabine With Aflibercept in Patients With Gastrointestinal and Breast Cancer.
10. Adjuvant chemotherapy for rectal cancer: Current evidence and recommendations for clinical practice.
11. PanCO: Updated Results of an Open-Label, Single-Arm Pilot Study of OncoSil P-32 Microparticles in Combination with Standard-of-Care (SoC) Gemcitabine + Nab-Paclitaxel or FOLFIRINOX Chemotherapy in Unresectable Locally Advanced Pancreatic Cancer (uLAPC)
12. Celyad's novel CAR T-cell therapy for solid malignancies.
13. Regorafenib in combination with immune checkpoint inhibitors for mismatch repair proficient (pMMR)/microsatellite stable (MSS) colorectal cancer.
14. Determination of the histological growth pattern of colorectal peritoneal metastases and evaluation of their prognostic impact.
15. Evaluation of the incidence of deep epigastric and cardiophrenic angle lymph nodes involvement, in patients with recurrent disease after cytoreductive surgery, for colorectal cancer.
16. Non-desmoplastic histological growth pattern predicts the risk of microscopically invaded margin and postoperative survival in patients undergoing resection of colorectal liver metastases.
17. Serial FDG–PET/CT for early outcome prediction in patients with metastatic colorectal cancer undergoing chemotherapy.
18. Phase I trial to investigate the safety, pharmacokinetics and efficacy of sorafenib combined with docetaxel in patients with advanced refractory solid tumours
19. Is Tailored Adjuvant Treatment for Colon Cancer Possible?
20. Prognostic Values of Galectin-3 and the Macrophage Migration Inhibitory Factor (MIF) in Human Colorectal Cancers.
21. Total neoadjuvant therapy for rectal cancer: Making sense of the results from the RAPIDO and PRODIGE 23 trials.
22. Selective internal radiation therapy simulation using 99mTc-labelled macroaggregates of albumin and SPECT-CT.
23. O-1 PanCO: Updated results of an open-label, single-arm pilot study of OncoSil P-32 microparticles in unresectable locally advanced pancreatic adenocarcinoma (LAPC) with gemcitabine + nab-paclitaxel or FOLFIRINOX chemotherapy.
24. Imaging and clinical correlates with regorafenib in metastatic colorectal cancer.
25. Grey areas and evidence gaps in the management of rectal cancer as revealed by comparing recommendations from clinical guidelines.
26. Recommendations for general surgeons facing incidental peritoneal carcinomatosis of colorectal origin.
27. 98 POSTER A Phase I study of sorafenib in combination with capecitabine in patients with advanced, solid tumors.
28. 426 Phase I study of oral CP-4126, a gemcitabine analog, in patients with advanced solid tumours.
29. 118 POSTER Percutaneous endoscopic gastrostomy in oncologic patients: “to do or not to do”?
30. LBA2 Interim efficacy analysis of REGINA, a phase II trial of neoadjuvant regorafenib (Rego), nivolumab (Nivo), and short-course radiotherapy (SCRT) in stage II-III rectal cancer (RC).
31. 505P State of the art of gastrointestinal (GI) cancer trials for older patients (pts): A systematic review (SR).
32. 159TiP COPERNIC: A study of on-treatment circulating tumour (ct)DNA changes in chemo-refractory colorectal cancer (CRC) patients.
33. Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142.
34. PD-1 and PD-L1 inhibitors in oesophago-gastric cancers.
35. 599P R-IMMUNE: A phase Ib/II study to evaluate safety and efficacy of atezolizumab combined with radio-chemotherapy in a preoperative setting for patients with locally advanced rectal cancer (LARC).
36. Treatment compliance in early-stage anal cancer.
37. Selective internal radiation therapy (SIRT) before partial hepatectomy or radiofrequency destruction for treatment of hepatocellular carcinoma in cirrhotic patients: a feasibility and safety pilot study.
38. 1308P Comparison of tumour size on outcomes for patients with unresectable locally advanced pancreatic adenocarcinoma (LAPC) receiving P-32 microparticles with standard-of-care chemotherapy (SoC CT).
39. Y90 radioembolization of colorectal cancer liver metastases: response assessment by contrast-enhanced computed tomography with or without PET-CT guidance.
40. Pooled analysis of the surgical treatment for colorectal cancer liver metastases.
41. P-276 Sex and regorafenib toxicity in refractory colorectal cancer: A safety analysis of the RegARd-C trial.
42. SO-27 Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142.
43. Short course chemotherapy followed by concomitant chemoradiotherapy and surgery in locally advanced rectal cancer: a randomized multicentric phase II study.
44. New strategies and designs in pancreatic cancer research: consensus guidelines report from a European expert panel†.
45. The relationship between heart rate variability and time-course of carcinoembryonic antigen in colorectal cancer
46. 1849P Safety and effectiveness of palliative chemotherapy (CTX) for patients (pts) with malignant bowel obstruction (MBO).
47. SO-009 - Phase 1 studies assessing the safety and clinical activity of autologous and allogeneic NKG2D-based CAR-T therapy in metastatic colorectal cancer.
48. PD-0420: Induction by mFOLFIRINOX followed by SIBSBRT for the neoadjuvant treatment of pancreatic cancer.
49. 517PClinical factors are unable to accurately predict the absence of benefit of surgery in patients operated for resection of colorectal liver metastasis.
50. LBA18_PRDurable clinical benefit with nivolumab (NIVO) plus low-dose ipilimumab (IPI) as first-line therapy in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC).
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.